Technology transfer arm of France's INSERM, managing IP and clinical translation across infectious disease, neurodegeneration, and precision medicine consortia.
INSERM Transfert is the technology transfer subsidiary of INSERM, France's national biomedical research institute. They manage intellectual property, clinical trial coordination, and project administration for INSERM's research teams participating in large European health consortia. Their role is to bridge the gap between publicly funded biomedical research and its translation into diagnostics, therapies, and vaccines — handling regulatory, contractual, and IP dimensions so that scientists can focus on the science. They bring professional project management and valorization expertise to multi-partner clinical and preclinical programs.
FAIR-PARK-II (Parkinson's iron chelation), MIROCALS (ALS immunotherapy), MEDIT-AGEING (Alzheimer's), JPsustaiND, and miniNO all involve neurological disease clinical development.
EBOVAC2 and CCHFVaccine (vaccine programs), EHVA (HIV vaccines), CARE and EU-RESPONSE (COVID-19), VHFMoDRAD and EbolaMoDRAD (rapid diagnostics), ZIKAlliance (Zika prevention).
ENSAT-HT (omics for endocrine hypertension), EU-TRAIN (kidney rejection biomarkers), R-LiNK (lithium response biomarkers), CARDIATEAM (omics for diabetic cardiomyopathy), HUGODECA (single-cell genomics), and EJP RD (rare disease omics).
EJP RD (European rare disease program), TheraLymph (gene therapy for lymphedema), and PREMSTEM (stem cell therapy for preterm brain injury).
ERINHA2 and ERINHA-Advance focus on building European infrastructure for highly pathogenic agent research.
REMEDIA (exposome impact on lung diseases) and OBERON (endocrine disruptors and metabolic disorders) represent a newer direction linking environment to health.
In 2014–2018, INSERM Transfert focused heavily on neurodegenerative disease trials (Parkinson's, ALS, Alzheimer's) and early infectious disease programs (Ebola diagnostics, HIV vaccines, Zika). From 2019 onward, their portfolio shifted markedly toward pandemic preparedness (COVID-19 response via CARE and EU-RESPONSE), environmental health (exposomes, endocrine disruptors), and advanced therapeutics like gene therapy and immunomodulation. The consistent thread is biomarker-driven translational medicine, but the application domains broadened significantly toward infectious disease preparedness and precision medicine.
INSERM Transfert is moving toward rapid-response infectious disease platforms and environmental health, making them a strong partner for future pandemic preparedness and exposome-related consortia.
INSERM Transfert never coordinates — across 33 projects, they serve exclusively as a participant or third party, providing technology transfer and project management services within large consortia. With 468 unique partners across 55 countries, they operate as a high-connectivity hub, linking French biomedical research capacity to an enormous international network. Their consistent presence in large RIA consortia (26 out of 33 projects) means they are experienced, low-friction partners who know how EU multi-site clinical programs work.
With 468 unique consortium partners spanning 55 countries, INSERM Transfert maintains one of the broadest collaboration networks in European health research. Their partnerships are genuinely global, covering not just EU member states but also African and Asian partners through infectious disease programs like EBOVAC2 and ZIKAlliance.
INSERM Transfert occupies a rare niche: they are a private company whose sole purpose is translating the research output of France's largest biomedical institute (INSERM, 13,000+ researchers) into clinical and commercial reality. Unlike academic partners who contribute research, or CROs who sell services, INSERM Transfert brings institutional knowledge of the entire INSERM research portfolio — making them a gateway to French biomedical expertise. For consortium builders, adding INSERM Transfert effectively means accessing INSERM's full bench-to-bedside pipeline with professional IP and regulatory management included.
